Skip to main content

Table 3 Multivariate survival analyses

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

  DFSª BCSSb OSb
  HR 95% CI P HR 95% CI P HR 95% CI P
BM3-pos vs. BM3-neg 2.2 1.3-3.9 0.005 2.6 1.4-4.7 0.002 2.6 1.4-4.4 0.002
cN status (vs. N0)    0.053    0.032    0.047
   cN1 2.0 1.0-3.8 0.040 2.3 1.1-4.8 0.019 2.2 1.1-4.3 0.024
   cN 2-4 2.4 1.0-5.6 0.034 2.7 1.1-6.6 0.027 2.4 1.0-5.6 0.049
PgR-pos vs. PgR-neg 1.3 0.7-2.7 0.429 1.8 0.9-3.8 0.118 1.5 0.8-3.1 0.239
ER-pos vs. ER-neg 0.9 0.4-2.0 0.796 1.0 0.5-2.4 0.919 0.9 0.4-2.1 0.897
PB1-pos vs. PB1-neg     2.2 0.3-19.1 0.482 2.2 0.3-17.8 0.496
Grade 3 vs.grade 1-2 1.1 0.8-1.5 0.648 1.1 0.6-2.3 0.703 1.3 0.7-2.5 0.482
  1. ªDisease-free survival (DFS) analyzed only in stage M0 patients.
  2. bBreast cancer-free survival (BCSS) and overall survival (OS) analyzed in all patients.
  3. Pos: positive; neg: negative; BM3: bone marrow aspiration pretreatment; cN: clinical node status; PgR: progesterone receptor; ER: estrogen receptor; PB1: peripheral blood sampling pretreatment.